anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Women were informed of the study, and their participation was requested. Those who offered their willingness to participate signed the informed consent and were randomly assigned to the intervention group (IG) or the control group (CG). Randomization was performed using Microsoft Excel spreadsheet software. All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from "gold-standard" training.
The present invention relates to a medicine, in particular to a medicinal composition and a preparation method thereof. The medicinal composition is used for nourishing blood, regulating menstruation, dispelling patch, improving facial splash of women, treating irregular menstruation and other diseases of women. The medicinal composition is prepared from raw materials of the following weight ratio: 80 grams of radix astragali, 40 grams of dodder, 50 grams of herba ecliptae, 40 grams of fructus ligustri lucidi, 40 grams of angelica, 50 grams of root of herbaceous peony, 40 grams of radix-polygoni multiflori, 50 grams of radix rehmanniae, 60 grams of prepared rhizome of rehmannia, 30 grams of peach kernel, 30 grams of radix bupleuri, 12 grams of ass-skin glue, 40 grams of Shoushen (Gymnadenia conopsea R.Br. (Orchidaceae)), 10 grams of safflower and 13 grams of starch. Compared with the prior art, the medicinal composition are made by high-quality, purely natural and pollution-free pure Tibet medicines in a scientific formula without toxic side effects. And the medicinal composition is suitable for treating qi and blood loss, facial scorch, chloasma, pigmentation, irregular menstruation and menopausal syndromes of women.
PURPOSE:To obtain the subject new analgesic excellent in analgesic and anti- inflammatory activity against burns, and also extremely high in safety, containing a glycoside of hydroquinone or an alkylhydroquinone as an active ingredient. CONSTITUTION:This anti-inflammatory analgesic for burns contains, as active ingredient, at least one kind of glycoside of hydroquinone or an alkylhydroquinone of the formula (R<1> is pentose residue, hexose residue, amino sugar residue, uronic residue or methylated product thereof; R<2> is H or a 1-4C alkyl) (e.g. arbutin, isohomoarbutin). The analgesic, as the form of a gel-like composition, pref. comprises 1.0-30wt.% of the glycoside of the formula, 5.0-40wt.% of a polyhydric alcohol, 0.005-20wt.% of a thickening agent and 1-30wt.% of a lower alcohol. The anti-inflammatory analgesic for burns can entirely obviate the pain and scars as a sequela of many patients.
Participants will be screened postpartum for inclusion. Only women with cesarean deliveries will be included as they are kept for 3 days in the hospital as opposed to 2 days for vaginal deliveries. If they meet inclusion criteria they will be asked to participate in the study, and consented. Each patient will receive routine postpartum care. The ambulatory blood pressure cuff will be introduced and validated on the particpant prior to discharge. Particpants will then be given specific instructions on when to place the cuff on their am and when to remove it. The ambulatory cuff will take blood pressure measurements every hour. The Particpant will be asked to keep a log of actives, symptoms, and pain medication use for the 72 hour period that her blood pressures are being recorded. The BP device will be returned to the department of OB/GYN at St. Mary's after completion of her 72 hours of monitoring. This will occur at her first post op visit. Particpants will be asked to complete a survey about comfort of device and return with the device. Information pertaining to their pregnancy and delivery will be collected while the patient is in the hospital. Particpants are not responsible for damage or loss of equipment.

All of these procedures are part of the study.
The invention discloses targeted DNA (deoxyribonucleic acid) naphthyldiimide-structure-containing celecoxib derivatives with antitumor activity, of which the structure is disclosed as Formula (I), wherein R is hydrogen, alkyl group or alkoxy group. The invention also discloses a preparation method of the derivatives and application of the derivatives in preparing drugs for resisting mammary cancer, cervical carcinoma and lung adenocarcinoma. The celecoxib structure is modified, and the naphthyldiimide group is used instead of sulfaphenyl group in the celecoxib, thereby designing and synthesizing a series of celecoxib derivatives containing the naphthyldiimide structure unit. The synthesized compounds 5a-5t have certain inhibiting actions on human mammary cancer cells, Hela cells and human lung adenocarcinoma cells. Part of the compounds have excellent antitumor activity, wherein the compounds 5o and 5h have very high selectivity for Hela cells, and the compound 5i has high selectivity for MCF-7 cells. The IC50 value is greatly lower than that of amonafide and higher than that of cis-platinum and celecoxib.
PROBLEM TO BE SOLVED: To obtain a stable composition excellent in feeling of use without generating loudiness by including aluminum lactate and an effective amount of a sugar alcohol therein. SOLUTION: This composition is prepared by formulating 10-30wt.% sugaralcohol (e.g. xylitol and/or sorbitol or mannitol) and regulating the pH to 5.5-7.5 with citric acid, tartaric acid, lactic acid, sodium borate, etc., in the composition for oral cavity prepared by formulating the aluminum lactate in a suitable solvent (water, ethanol or a denatured alcohol). Various pharmacodynamic ingredients, a humectant, a foaming agent, etc., (e.g. propylene glycol, an algal extract, a carboxyvinyl polymer, a lysozyme chloride or a dextranase) can be added thereto unless the effects thereof are not deteriorated. The composition is capable of assuming the form such as a liquid dentifrice or a mouthwash.
The present invention relates to novel salt forms of a compound of Formula (I): and processes for their preparation. The present invention relates to novel salt forms of a compound of Formula (I): and processes for their preparation. Devices and methods for delivering a chemical compound to, through or into a membrane, tissue or layer are provided. The device may include an AC signal source and at least one electrode. In one application, an interdigitated electrode may be electrically connected to the AC signal source. In one application, the chemical compound such as a medicament containing a drug may be disposed on or within the electrode and logic may control the AC signal source to provide the signal, including setting or selecting characteristics such as voltage, frequency and the like to orient and/or motivate an amount of the chemical compound through the electrode and into the tissue.
Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
BACKGROUND: This paper aimed to explore the prevalence of temporomandibular disorders (TMDs) signs/symptoms, and to investigate the possible link between signs/symptoms of TMDs and mouth breathing (MB) by evaluating along with other risk factors, in a Turkish subpopulation of children and adolescence.
METHODS: This study was conducted with the archival data of the patients who applied with orthodontic complaints. Data on demographic characteristics, family-related factors, systemic status, occlusion, breathing patterns, oral habits, and bruxism were retrieved from the archival records.
RESULTS: Nine hundred forty-five children and adolescents with a mean age of 14.82 ± 2.06 years were included in the study. Of the participants, 66% were girls, 60.4% were delivered by C-section, 8.4% of the participants had at least one systemic disease, 9.2% of the participants had allergy, and 4.3% of the participants' parents were divorced, 18.7% have an oral habit, 6.6% have bruxism, 29.8% have malocclusion and 14.1% have MB. Eight-point-five percent of participants have signs/symptoms of TMD. Among them 2.9% have pain, 3.7% have joint sounds, 1.4% have deflection, and 3.9% have deviation. Evaluation of the risk factors revealed a significant relation between the signs/symptoms of TMD and bruxism (OR 8.07 95% CI 4.36-14.92), gender (OR 2.01 95% CI 1.13-3.59), marital status of parents (OR 2.62 95% CI 1.07-6.42), and MB (OR 3.26 95% CI 1.86-5.71).
CONCLUSIONS: According to the study's findings, girls and those with bruxism, divorced parents, and MB behavior are more likely to have signs/symptoms of TMD. Age found to have significant effect on the occurrence of the signs/symptoms of TMD alone, but together with other factors the effect of the age is disappeared. Early screening and intervention of MB as well as the signs/symptoms of TMD can help to limit detrimental effects of these conditions on growth, and quality of life of children and adolescents.
BACKGROUND: Remimazolam is an ultrashort-acting benzodiazepine that is increasingly used for its efficacy in anesthesia induction and maintenance. However, limited research has explored its impact on intraoperative hypothermia compared to that of traditional inhalation anesthetics. This study aimed to compare the incidence of hypothermia during endoscopic nasal surgery when using remimazolam for maintenance anesthesia versus using inhalation anesthetics.
METHODS: This prospective study included 70 patients who underwent endoscopic nasal surgery under general anesthesia. The patients were randomly assigned to one of two groups: the inhalation anesthetic (IA) group (n=35), in which desflurane and nitrous oxide were administered, and the remimazolam (R) group (n=35), in which remimazolam and remifentanil were administered for anesthesia maintenance. The primary outcome was the incidence of intraoperative hypothermia, defined as an esophageal temperature below 36 °C during anesthesia.
RESULTS: The incidence of intraoperative hypothermia was significantly higher in the R group than in the IA group (P = 0.014). Furthermore, the temperature at the end of the surgery was significantly lower in the R group than in the IA group (P = 0.006). Additionally, the use of warming devices after surgery was more frequent in the R group than in the IA group (P = 0.047).
CONCLUSIONS: These findings suggest that the use of remimazolam for maintenance anesthesia during endoscopic nasal surgery increases the risk of intraoperative hypothermia compared to the use of inhalation anesthetics. This highlights the importance of temperature monitoring in patients receiving remimazolam to minimize the adverse outcomes associated with hypothermia during surgery.
Healthy participants received a single dose of rivaroxaban 10 mg orally on day 1 (phase 1) followed by cobicistat 150 mg once daily from days 2 - 7 and a single dose of rivaroxaban 10 mg on day 7 (phase 2). Participants received darunavir /cobicistat 800/150 mg once daily from days 8 - 13 followed by a single dose of rivaroxaban 10mg on day 13 (phase 3). Serial blood sampling was done on days 1, 7, and 13.
The aim of this study is to examine the effects of using insulin administration video and insulin administration brochure as teaching materials in insulin administration training given to type 2 diabetes patients on correcting insulin administration errors. This randomized controlled experimental study was carried out with 94 people who applied to the diabetes outpatient clinic of Istanbul Medeniyet University Goztepe Training and Research Hospital between December 2019 and January 2021. Using a computer-based randomization method, 52 and 42 people were assigned to the groups that received training with video and brochures, respectively. In the first interview, patients' insulin administration characteristics were evaluated, and the training was repeated using the video or brochure, after which the training material corresponding to the group according to the randomization list was given. Insulin administration characteristics of the patients were re-evaluated one week and three months later. Patient information form developed by the researcher based on the literature was used to collect the data. Data were analysed using descriptive statistics, independent sample t-test and Mann Whitney U test. The error rates in the interviews were analysed with the Cochrane Q test, and the relationship between independent categorical variables was examined with the Chi-square test.
BACKGROUND: There was controversy surrounding the optimal thromboprophylaxis strategy for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of anticoagulants for thromboembolism prophylaxis, the requirement for additional antiplatelet therapy, and the necessity of prophylaxis for outpatients and postdischarge. To explore this, the authors performed a meta-analysis of randomized controlled trials.
METHODS: PubMed, Cochrane Library, Embase, and Web of Science were last searched on 26 July 2023 for studies comparing the effect of different dose of anticoagulation, additional antiplatelet, and postdischarge prophylaxis for COVID-19 patients. The results of eligible studies were analyzed in terms of thromboembolism events, major bleeding and all-cause mortality during follow-up.
RESULTS: Our study included a total of 25 randomized controlled trials, involving 17 911 patients. Our results revealed that, compared to prophylactic dose, therapeutic dose showed lower thrombotic risk (RR, 0.66; 95% CI: 0.45-0.96) but had similar major bleeding risk for critically ill patients with COVID-19. On the other hand, intermediate dose and prophylactic dose demonstrated similar thromboembolism risk and major bleeding risk. For noncritically ill patients with COVID-19, therapeutic dose of anticoagulants was associated with lower thrombotic risk (RR, 0.50; 95% CI: 0.34-0.72) but, at the same time, increased the risk of major bleeding (RR, 2.01; 95% CI: 1.22-3.33). However, intermediate dose showed lower thromboembolism risk (RR, 0.38; 95% CI: 0.21-0.69) while maintaining a similar major bleeding risk. In critically ill patients, additional antiplatelet therapy showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For outpatients, additional prophylactic anticoagulation showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For postdischarge patients, postdischarge prophylaxis reduced thromboembolism risk (RR, 0.49; 95% CI: 0.31-0.76) but increased major bleeding risk (RR, 2.63; 95% CI: 1.13-6.14).
CONCLUSION: For noncritically ill patients, therapeutic dose prophylactic anticoagulation significantly reduced venous thromboembolism but increases major bleeding risk. Intermediate dose effectively lowered venous thromboembolism without raising major bleeding risk. The optimal dose and need for additional antiplatelet therapy in critically ill patients, as well as the necessity of prophylactic anticoagulation in outpatient and postdischarge patients, required further investigation and confirmation through rigorous evidence studies.
BACKGROUND: Human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes have been reported to be effective in the treatment of cancer. The miR-214-3p is a suppressor miRNA that has been extensively studied and has been proposed as a diagnostic and prognostic biomarker in some cancers.
OBJECTIVES: The aim of this study was to investigate whether the regulatory mechanism of hucMSC-derived exosomal miR-214-3p with GLUT1 and ACLY affects the proliferation and apoptosis of gallbladder cancer (GBC) cells.
MATERIAL AND METHODS: We found that the target genes of miR-214-3p on the TargetScan website contain GLUT1 and ACLY, and the targeting relationship was verified using luciferases. The GBC-SD cells overexpressing GLUT1 and ACLY were constructed to determine proliferation, apoptosis, migration, and other cellular activities.
RESULTS: We identified hucMSCs and exosomes, and found that the exosomes contained miR-214-3p. Furthermore, TargetScan predicted that miR-214-3p had base interactions with ACLY. Dual luciferase assays showed that miR-214-3p could inhibit ACLY (p < 0.05). The results of quantitative reverse transcription polymerase chain reaction (RT-qPCR) and western blot showed that exosomal miR-214-3p could inhibit the expression of ACLY and GLUT1 (p < 0.05). Exosomal miR-214-3p can inhibit the proliferation, cloning and migration of GBC-SD cells (p < 0.05). The apoptosis of GBC-SD cells was increased (p < 0.05). The GBC-SD cells overexpressing ACLY and GLUT1 could reverse the efficacy of miR-214-3p.
CONCLUSIONS: Exosomal miR-214-3p can inhibit the downstream expression of ACLY and GLUT1. The ACLY and GLUT1 could affect the proliferation and apoptosis of GBC-SD cells.
A communication device (CD) exchanges messages with an implantable infusion pump via telemetry such that commands are supplied thereto and operational information is obtained therefrom. The CD is controlled, at least in part, by a processor IC according to a software program operating therein and provides feedback to a user via a visual display, an audio alarm, and a vibrational alarm, and allows input from the user via a touch sensitive keypad. Certain input functions are restricted by password. The visual display includes an icon and fixed element display region and a bitmap display region. The fixed element display region includes time and date displays, battery and drug level displays that decrement, and a moving delivery state display. Various screens allow operational or log information to be displayed and/or user entry of commands. Program features when disabled are removed from a series of screen options that can be scrolled through.
FIELD: medicine. SUBSTANCE: the suggested method deals with successive cyclic heating and cooling the whole body surface, excluding the head. Cooling should be performed by applying ozone-containing medicinal substance (gaseous mixtures, aerosol gas-liquid compositions of medicinal substances) at simultaneous function of cooling agent. The quantity of heating-cooling cycles in one seance of continuous technological process of thermo-contrast impact should correspond to 1, not less. Heating-cooling should be carried out in certain temperature and time mode. The method in question provides higher supply of ozone-containing substances per one therapeutic seance. EFFECT: shortened terms of therapy. 1 cl, 5 dwg, 3 ex, 1 tbl
An in vitro construction method and use of liver organoids. Mouse hepatocytes are extracted and induced to construct liver organoids, the morphology of the liver organoids is observed under a microscope, and the sternness and epithelial cell attributes of the liver organoids are identified by immunofluorescence and PCR. Acute liver failure (ALF) mouse models undergoing 70% liver resection are established and transplanted with the liver organoids, liver function is evaluated on day 1, day 4, and day 7 after the transplantation, and liver weight-to-body weight ratios are compared. The therapeutic effect of the liver organoids on ALF is verified by HE staining and immunohistochemistry. Inflammation and proliferation indexes such as HE staining and ki-67 staining show that the proliferation is enhanced after the liver organoids are transplanted. The liver organoids can alleviate the liver function failure and increase the liver weight-to-body weight ratio of ALF mice undergoing 70% liver resection.
PURPOSE: Hemorrhage is the leading cause of pediatric death in trauma and cardiac arrest during surgery. Adult studies report improved patient outcomes using massive hemorrhage protocols (MHPs). Little is known about pediatric MHP adoption in Canada.
METHODS: After waived research ethics approval, we conducted a survey of Canadian pediatric tertiary care hospitals to study MHP activations. Transfusion medicine directors provided hospital/patient demographic and MHP activation data. The authors extracted pediatric-specific MHP data from requested policy/procedure documents according to seven predefined MHP domains based on the literature. We also surveyed educational and audit tools. The analysis only included MHPs with pediatric-specific content.
RESULTS: The survey included 18 sites (100% response rate). Only 13/18 hospitals had pediatric-specific MHP content: eight were dedicated pediatric hospitals, two were combined pediatric/obstetrical hospitals, and three were combined pediatric/adult hospitals. Trauma was the most common indication for MHP activation (54%), typically based on a specific blood volume anticipated/transfused over time (10/13 sites). Transport container content was variable. Plasma and platelets were usually not in the first container. There was little emphasis on balanced plasma/platelet to red-blood-cell ratios, and most sites (12/13) rapidly incorporated laboratory-guided goal-directed transfusion. Transfusion thresholds were consistent with recent guidelines. All protocols used tranexamic acid and eight sites used an audit tool.
DISCUSSION/CONCLUSION: Pediatric MHP content was highly variable. Activation demographics suggest underuse in nontrauma settings. Our findings highlight the need for a consensus definition for pediatric massive hemorrhage, a validated pediatric MHP activation tool, and prospective assessment of blood component ratios. A national pediatric MHP activation repository would allow for quality improvement metrics.
Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the "No intervention"-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise.